The integrated 31-gene expression profile (i31-GEP) test for cutaneous melanoma outperforms CP-GEP at identifying patients who can safely forego sentinel lymph node biopsy
Main Article Content
Keywords
integrated 31-gene expression profile, i31-GEP, cutaneous melanoma, CP-GEP, prognosis, sentinel lymph node biopsy
References
2. Vickers et al. BMJ 2015
3. Vickers et al. Diagn Progn Res. 2019
4. Whitman et al. JCO PO 2021
5. Vetto et al. Future Oncology. 2019
6. Hsueh et al. JCO PO 2021
7. Jarell et al. JAAD. 2022
8. Arnot et al. AJS. 2021
9. Dillon et al. CMRO.2022
10. Ahmed et al. Cancer Med. 2022
11. Bellomo et al. JCO PO 2020
12. Yousaf et al. IJD 2021
13. Mulder et al. BJD 2020
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.